Table 1.
Clinical characteristics of patients in the short-, intermediate-, and long-wait groups.
| Varible | All patients (n = 316) | SWT (days) Short <31 (n = 173) | Intermidiate [31,90] (n = 69) | Long >90 (n = 74) | P |
|---|---|---|---|---|---|
| Age (yr) | 69 (61-75) | 69 (59-75) | 69 (68-79) | 68 (61-75) | 0.376 |
| Sex | 0.352 | ||||
| Male | 205 | 110 (34.8%) | 42 (13.3%) | 53 (16.8%) | |
| Female | 111 | 63 (19.9%) | 27 (8.5%) | 21 (6.7%) | |
| Smoke | 0.511 | ||||
| Yes | 70 | 34 (10.8%) | 17 (5.4%) | 19 (6.1%) | |
| No | 245 | 138 (43.7%) | 52 (16.5%) | 55 (17.5%) | |
| ECOG performance status | 0.986 | ||||
| 0 | 199 | 109 (34.6%) | 43 (13.7%) | 47 (14.9%) | |
| 1 | 116 | 63 (19.9%) | 26 (8.3%) | 27 (8.6%) | |
| Median Body mass index (kg/m2) | 22.6 (20.1-25.2) | 22.5 (20.4-24.7) | 22.4 (20.1-24.9) | 22.8 (19.7-25.3) | 0.120 |
| Haematuria | 0.000 | ||||
| (+) | 223 | 95 (30.1%) | 58 (18.4%) | 70 (22.2%) | |
| (-) | 91 | 77 (24.4%) | 11 (3.5%) | 3 (0.9%) | |
| Hydronephrosis | 0.429 | ||||
| (+) | 158 | 92 (29.1%) | 33 (10.4%) | 33 (10.4%) | |
| (-) | 158 | 81 (25.6%) | 36 (11.4%) | 41 (13.1%) | |
| Tumor location | 0.032 | ||||
| Renal pelvis | 173 | 84 (26.6%) | 40 (12.7%) | 49 (15.5%) | |
| Ureter | 143 | 89 (28.2%) | 29 (9.2%) | 25 (7.8%) | |
| Tumor grade | 0.311 | ||||
| High | 234 | 132 (41.8%) | 52 (16.5%) | 50 (15.8%) | |
| Low | 81 | 40 (12.8%) | 17 (5.4%) | 24 (7.7%) | |
| Tumor size | 3.5 (2.5-5) | 3.5 (2.5-5.0) | 3.5 (2.5-4.8) | 3.0 (2.0-5.0) | 0.949 |
| Amount of lesions | 0.137 | ||||
| Single | 270 | 144 (45.6%) | 64 (20.1%) | 62 (19.6%) | |
| Mutiple | 45 | 29 (9.2%) | 5 (1.6%) | 12 (3.9%) | |
| pT stage | 0.310 | ||||
| ≤pT1 | 87 | 51 (16.1%) | 14 (4.4%) | 22 (7.0%) | |
| pT2 | 111 | 54 (17.0%) | 30 (9.5%) | 27 (8.4%) | |
| pT3 | 97 | 57 (18.0%) | 17 (5.3%) | 23 (7.3%) | |
| pT4 | 21 | 11 (6.6%) | 8 (3.4%) | 2 (0.6%) | |
| Lymph node involvement | 0.706 | ||||
| pN0 | 282 | 151 (47.8%) | 64 (20.3%) | 67 (21.1%) | |
| pN+ | 34 | 22 (7.0%) | 5 (1.6%) | 7 (2.2%) | |
| LND | 0.861 | ||||
| Yes | 81 | 46 (14.6%) | 16 (5.1%) | 19 (6.0%) | |
| No | 235 | 127 (40.2%) | 53 (16.8%) | 55 (17.4%) | |
| Surgical approch | 0.352 | ||||
| Open | 67 | 37 (11.7%) | 18 (5.7%) | 12 (3.9%) | |
| Laparoscopy | 249 | 136 (43.0%) | 51 (16.1%) | 62 (19.6) | |
| Surgical margin | 1.000 | ||||
| Positive | 0 | 0 ( 0.0%) | 0 (0.0%) | 0 (0.0%) | |
| Negative | 316 | 173 (54.7%) | 69 (21.8%) | 74 (23.4%) | |
| Tumor necrosis | 0.789 | ||||
| Yes | 87 | 48 (15.2%) | 17 (5.4%) | 22 (7.0%) | |
| No | 229 | 125 (39.6%) | 52 (16.5%) | 52 (16.5%) | |
| Infiltrative tumor | 0.313 | ||||
| Architecture | |||||
| Yes | 229 | 122 (38.6%) | 55 (17.4%) | 52 (16.5%) | |
| No | 87 | 51 (16.1%) | 14 (4.4%) | 22 (7.0%) | |
| lymphovascular invasion | 0.128 | ||||
| Yes | 38 | 26 (8.2%0 | 4 (1.3%) | 8 (2.5%) | |
| No | 278 | 147 (46.5%) | 65 (16.5%) | 66 (20.9%) | |
| Complicated with bladder cancer | |||||
| Yes | 20 | 10 (3.2%) | 5 (1.6%) | 5 (1.6%) | 0.901 |
| No | 296 | 163 (51.6%) | 64 (20.3%) | 69 (21.8%) |
ECOG, Eastern Cooperative Oncology Group.